Health and Medical Devices News
Samenvatting: TomTec introduceert 4D MV-Assessment, de nieuwe 3D-toepassing voor betere diagnoses bij mitraalkleppen tijdens het ESC (European Society of Cardiology) congres in Stockholm
MUNICH, Duitsland--(BUSINESS WIRE)--TomTec Imaging Systems GmbH introduceert vandaag zijn nieuwe 4D MV-Assessment 2.0 software. Deze 4D MV-Assessment software combineert de kracht van 2D met de voordelen van 3D echocardiografie om de arts de belangrijke en deels ongekende diagnostische informatie en metingen van de mitraalklep te geven. Het wordt steeds normaler om ook symptoomvrije patiënten met mitralisinsufficiëntie te opereren. Deze bekendmaking is officieel geldend in de originele brontaal.
…
Enzo Biochem’s Clinical Lab Takes Major Step in Becoming National Provider of Predictive Diagnostics
NEW YORK--(BUSINESS WIRE)--In the first of several moves to expand the Company’s position as a national provider of esoteric and high value diagnostics, Enzo Biochem, Inc. (NYSE:ENZ) announced today that its Enzo Clinical Labs division has been awarded a license for doing business in the Commonwealth of Pennsylvania, the first of several for which it has applied. “Patient care is moving increasingly to predictive diagnostics utilizing markers and gene based programs, and Enzo Clinical Labs, owin
…
爱尔康独立董事委员会通知：诺华完成对雀巢所持爱尔康股权的收购
瑞士HUENENBERG--(BUSINESS WIRE)--(美国商业资讯)--爱尔康（Alcon）独立董事会得知诺华公司（Novartis AG）已完成对雀巢公司所持爱尔康公司股权的收购。该交易使诺华持有的爱尔康股权增至约77%，是按照雀巢与诺华于2008年4月6日签订的《购股及选择权协议》完成的。雀巢/诺华交易的完成符合预期，且不会对独立董事委员会在诺华对少数股东的合并提议一事上的立场造成影响。 独立董事委员会主席Thomas G. Plaskett说：“我们希望能够协商一笔体现爱尔康少数股东公允价值的交易。取得协商一致的交易最能体现所有利益相关方的最大利益，而且显然比冗长的诉讼程序更可取，诉讼必将造成整合过程中一些关键步骤的延迟。但如果诺华拒绝就公平交易展开协商，我们也愿意维护爱尔康及其少数股东的权益。” 雀巢/诺华交易的完成实现了向爱尔康董事会增派5名由诺华指派的董事所需的条件，这一做法虽然遭到了少数股东的大力反对，但已于8月16日完成。就所有关于诺华对少数股东的合并提议一事的决策而言，这些由诺华指派的董事显然存在利益冲突。正如独立董事委员会此前公布且得到领先的瑞士公司治理专
…
Pico-Tesla Expands Operations to Midwest Region
LITTLETON, Colo.--(BUSINESS WIRE)--New facility in Novi (Detroit), Mich., complements sites in Littleton, Colo., and Clearwater, Fla.
…
TomTec présente 4D MV-Assessment, la nouvelle solution 3D qui améliore la fiabilité du diagnostic lors des interventions thérapeutiques au niveau de la valvule mitrale, lors du congrès de la Société européenne de cardiologie à Stockholm
MUNICH, Allemagne--(BUSINESS WIRE)--TomTec Imaging Systems GmbH a annoncé aujourd'hui la présentation de son nouveau logiciel 4D MV-Assessment© 2.0. Ce logiciel combine tous les atouts de la 2D avec les avantages de l'échocardiographie 3D pour offrir au médecin d'importantes informations et mesures de diagnostic, pratiquement sans précédent, concernant la valvule mitrale. La tendance à opérer des patients asymptomatiques souffrant de régurgitation mitrale se généralise. Grâce à ses données échoc
…
Novella Clinical Appoints Vice President, Clinical Operations in Europe
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Novella Clinical Inc. announced today that it has appointed Jane Bentley PhD, as Vice President, Clinical Operations. Dr. Bentley is responsible for leading European clinical operations for Novella, as well as promoting the company’s values, vision and growth. Jane has a wealth of clinical research experience having worked with large pharma, including GlaxoSmithKline and Roche, as well as with CROs and the service sector. She joins Novella after a 1
…
Answerthink Joins SAP Business All-in-One Fast-Start Program
MIAMI--(BUSINESS WIRE)--Answerthink Joins SAP Business All-in-One Fast-Start Program; Enables Midsize Life Sciences Companies To Achieve Faster Implementations and ROI
…
Riassunto: TomTec presenta 4D MV-Assessment, la nuova soluzione a 3D per una diagnostica migliore e più sicura nella terapia della Valvola mitrale presso il congresso ESC (European Society of Cardiology) di Stoccolma
MONACO, Germania--(BUSINESS WIRE)--TomTec Imaging Systems GmbH ha annunciato oggi l'introduzione del suo nuovo software 4D MV-Assessment© 2.0. Il software 4D MV- Assessment abbina la forza del 2D con i vantaggi dell'ecocardiografia a 3D per offrire al medico dati diagnostici importanti e in parte inediti e valutazioni per la Valvola mitrale. La tendenza ad operare pazienti anche asintomatici che soffrono di rigurgito mitrale diventa sempre più significativa. Utilizzando gruppi di dati ecocardiog
…
Bio-Reference Laboratories, Inc. Announces 25% Revenue Growth, 17% Patient Growth, Record Income
ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Bio-Reference Laboratories, Inc. Announces 25% Revenue Growth, 17% Patient Growth, Record Income
- - -
The Company reported strong growth in all areas of its business
…
BZresources to Present at Legal IQ/IQPC 5th eDiscovery for Pharma, Biotech & Medical Device Industries Conference
SAN FRANCISCO--(BUSINESS WIRE)--BZresources, the e’discovery practice support division for the law firm of Bartko, Zankel, Tarrant & Miller, announced it will participate in Legal IQ/IQPC 5th eDiscovery for Pharma, Biotech & Medica
…
Medtronic Receives Health Canada Approval for the Newest Radiofrequency Ablation Tools for Atrial Fibrillation
MINNEAPOLIS & BRAMPTON, Ontario--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced it received Health Canada approval for the Medtronic Ablation Frontiers Cardiac Ablation System, a novel radiofrequency (RF) ablation technology for the treatment of atrial fibrillation (AF). AF is the most common heart arrhythmia that affects more than 250,000 Canadians1 and seven million people worldwide.2 The Medtronic Ablation Frontiers Cardiac Ablation System tools now approved for use in Canada in
…
Medtronic reçoit de Santé Canada l’homologation de ses tout nouveaux outils d’ablation de la fibrillation auriculaire par radiofréquence
MINNEAPOLIS & BRAMPTON, Ontario--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) a annoncé aujourd’hui qu’elle a reçu de Santé Canada l’homologation du système d’ablation cardiaque Ablation Frontiers de Medtronic, une nouvelle technologie d’ablation par radiofréquence (RF) pour le traitement de la fibrillation auriculaire (FA). La FA est un type d’arythmie cardiaque le plus répandu; elle affecte plus de 250 000 Canadiens1 et sept millions de personnes à l’échelle mondiale.2 Les outils du système d’
…
Samenvatting: Novartis voltooit aankoop meerderheidsbelang Alcon van Nestlé
HUENENBERG, Switzerland--(BUSINESS WIRE)--Novartis AG (NYSE: NVS) en Nestlé S.A. maken vandaag bekend de koop en verkoop te hebben afgerond van ongeveer 156 miljoen aandelen van Alcon, Inc. (NYSE: ACL) voor 28,3 miljard dollar in contanten. De transactie werd voltooid in navolging van een overeenkomst tussen Nestlé en Novartis vastgelegd op 6 april 2008. Na voltooiing van deze transactie is Novartis met ongeveer 77 procent van de uitstaande aandelen in bezit de grootste aandeelhouder van Alcon.
…
Alcon Independent Director Committee noteert afronding overname Novartis van belang Nestlé in Alcon
HUENENBERG, Switzerland--(BUSINESS WIRE)--Het Alcon Independent Director Committee (het “IDC”) noteert de afronding van de overname van Novartis AG (“Novartis”) van het resterende belang van Nestlé SA (“Nestlé”) in Alcon, Inc. (“Alcon”). De transactie vergroot het belang van Novartis in Alcon tot ongeveer 77 procent. De transactie werd voltooid volgens de overeenkomst aangegaan door Nestlé en Novartis op 6 april 2008. De afronding werd verwacht en heeft geen gevolgen voor de positie van IDC met
…
Fresenius Medical Care Acquires Peritoneal Dialysis Business from Gambro
BAD HOMBURG, Germany--(BUSINESS WIRE)--Fresenius Medical Care acquires peritoneal dialysis business from Gambro
…
Riassunto: Il comitato di amministratori indipendenti di Alcon registra la chiusura dell'acquisizione da parte di Novartis della quota di Nestlé in Alcon
HUENENBERG, Svizzera--(BUSINESS WIRE)--Il Comitato amministratori indipendenti di Alcon (Independent Director Committee, “IDC”) registra la chiusura dell'acquisizione da parte di Novartis AG (“Novartis”) della quota restante di Nestlé SA (“Nestlé”) in Alcon, Inc. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unic
…
Riassunto: Novartis completa acquisto da Nestlé di interesse di maggioranza su Alcon
HUENENBERG, Svizzera--(BUSINESS WIRE)--Novartis AG (NYSE: NVS) e Nestlé S.A. hanno annunciato oggi di avere completato l'acquisto e la vendita di circa 156 milioni di azioni di Alcon, Inc. (NYSE: ACL) per USD 28,3 miliardi in contanti. La transazione si è svolta ai sensi di un accordo tra Nestlé e Novartis che è stato eseguito il 6 aprile 2008. Con il completamento di questa transazione, Novartis è adesso azionista di maggioranza di Alcon e controlla circa il 77 per cento delle azioni emesse di
…
TomTec stellt 4D MV-Assessement, die neue 3D Lösung für mehr Diagnosesicherheit bei der Mitralklappentherapie auf dem ESC (European Society of Cardiology) Kongress in Stockholm vor
MÜNCHEN, Deutschland--(BUSINESS WIRE)--Heute hat die TomTec Imaging Systems GmbH die Einführung ihrer neuen 4D MV-Assessment© Software angekündigt. Das 4D MV-Assessment Upgrade kombiniert die Stärken von 2D mit den Vorteilen von 3D Ultraschall, um dem Arzt wichtige und teilweise noch nie da gewesene diagnostische Informationen und Messungen für die Mitralklappe zu liefern. Der Trend auch asymptomatische Patienten die an Mitralklappeninsuffizienz leiden zu operieren wird immer wichtiger. Durch di
…
TomTec introduces 4D MV-Assessment, the new 3D solution for improved diagnostic confidence in Mitral Valve therapy at the ESC (European Society of Cardiology) congress in Stockholm
MUNICH, Germany--(BUSINESS WIRE)--TomTec introduces new 4D MV-Assesment at upcoming ESC congress
…
Der unabhängige Verwaltungsratsausschuss der Alcon nimmt Kenntnis vom Vollzug der Übernahme des Alcon-Anteils von Nestlé durch Novartis
HÜNENBERG, Schweiz--(BUSINESS WIRE)--Der unabhängige Verwaltungsratsausschuss («IDC») von Alcon nimmt Kenntnis vom Vollzug der Übernahme des noch bestehenden Anteils der Nestlé AG («Nestlé») an der Alcon, Inc. («Alcon») durch die Novartis AG («Novartis»). Die Transaktion, durch die der Anteil von Novartis an Alcon auf rund 77 Prozent erhöht wird, erfolgte gemäss dem «Purchase and Option Agreement» zwischen Nestlé und Novartis vom 6. April 2008. Der Vollzug der Transaktion zwischen Nestlé und Nov
…
